Kongensin A is primarily studied for its potential as an anti-cancer agent. It functions as a potent inhibitor of heat shock protein 70 (Hsp70), a molecular chaperone involved in protein folding and cellular stress response. By targeting Hsp70, Kongensin A disrupts the stability and function of client proteins that are critical for cancer cell survival, leading to apoptosis in tumor cells. This makes it a promising candidate for development in oncology, especially in cancers where Hsp70 is overexpressed, such as certain types of leukemia, breast cancer, and prostate cancer. Additionally, Kongensin A has shown activity in overcoming drug resistance in cancer therapy by interfering with Hsp70-mediated protective mechanisms. Its role in modulating protein homeostasis also opens avenues for research in neurodegenerative diseases, where misfolded proteins accumulate. However, most studies remain in the preclinical stage, focusing on mechanism of action and efficacy in cell and animal models.